Dec 17 (Reuters) - Indivior ( INDV ) said on Tuesday its

finance chief Ryan Preblick will step down as the British

drugmaker makes changes to its board following pressure from No.

2 shareholder Oaktree Capital.

The maker of opioid addiction treatment Sublocade has been

engaged in conversations with Oaktree Capital Management

following the investment fund's repeated calls for the drugmaker

to refresh its board and take strategic actions to recover its

falling market share.

Indivior ( INDV ) also appointed Robert Schriesheim and Joe Ciaffoni

as independent non-executive directors, and said it has agreed

to move towards a more standard U.S. system of remuneration for

directors following its recent primary listing in New York.

"We believe the constructive actions Indivior's ( INDV ) Board has

undertaken, together with the appointment of these new

independent directors, will accelerate the Company's operational

execution and enhance long-term shareholder value," said Andrew

West, Managing Director in Oaktree's Value Opportunities Group.

In October, the company had issued its second profit and

revenue warning in the span of three months after sales for

Sublocade remained weak against Swedish pharmaceutical firm

Camurus' competing drug Brixadi.